Please try another search
For the fiscal year ended 31 December 2021, Lumibird SA revenues increased 28% to EUR162.5M. Net income increased from EUR5.6M to EUR13.9M. Revenues reflect Medicinal segment increase of 49% to EUR86.1M, Photonique segment increase of 11% to EUR76.4M, Other segment increase of 43% to EUR81.9M, USA segment increase of 25% to EUR30.3M. Net income benefited from Other Income/Expenses decrease of 97% to EUR110K (expense).
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Revenue | 87.03 | 75.44 | 80.96 | 45.77 |
Gross Profit | 55.64 | 47.64 | 46.41 | 30.36 |
Operating Income | 11.16 | 7.97 | 10.81 | -2.15 |
Net Income | 8.79 | 5.07 | 7.57 | -1.93 |
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Assets | 347.62 | 311.98 | 305.43 | 295.65 |
Total Liabilities | 166.29 | 142.19 | 141.34 | 139.33 |
Total Equity | 181.33 | 169.79 | 164.09 | 156.32 |
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Period Length: | 12 Months | 6 Months | 12 Months | 6 Months |
Cash From Operating Activities | 26.57 | 8.08 | 13.12 | -0.84 |
Cash From Investing Activities | -28.63 | -7.65 | -67.14 | -59.04 |
Cash From Financing Activities | 18.2 | -1.02 | 84.76 | 88.8 |
Net Change in Cash | 16.79 | -0.34 | 30.12 | 28.73 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review